Analyst firms · Oppenheimer · INSP

Oppenheimer INSP price target and rating history

Inspire Medical Systems Inc. (INSP) · Health Care

Oppenheimer rates Inspire Medical Systems Inc. (INSP) Outperform with a $85 price target, as of its latest action on Aug 4, 2026. It has published 3 rating actions on INSP since December 2025, including 2 upgrades and 1 downgrade. Across 12 firms with a INSP price target in the last 12 months, the median target is $72. Oppenheimer's $85 is 18% above that.

Current rating
Outperform
Price target
$85
Median target, all firms
$72
Actions on INSP
3

Oppenheimer price target on INSP

$175$130$852026
Oppenheimer price target on INSP, each point a stated target, December 2025 to August 2026.

Every Oppenheimer rating on INSP

How other firms rate INSP

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
BarclaysUnderweight$65Oct 7, 2026
OppenheimerOutperform$85Aug 4, 2026
UBSSell$39Jul 28, 2026
Evercore ISIIn-line$40Jun 23, 2026
BofA SecuritiesUnderperform$39May 22, 2026
Piper SandlerNeutral$55May 5, 2026
Wolfe ResearchPeer Perform$180Feb 13, 2026
Robert W. BairdNeutral$74Feb 12, 2026
Wells FargoEqual Weight$70Feb 12, 2026
RBC Capital MarketsSector Perform$90Jan 27, 2026
Truist SecuritiesHold$96Jan 22, 2026
Morgan StanleyEqual-Weight$130Dec 2, 2025
StifelBuyNov 24, 2025

Questions about Oppenheimer and INSP

What is Oppenheimer's price target for INSP?
Oppenheimer's latest stated price target for Inspire Medical Systems Inc. (INSP) is $85, from its action on Aug 4, 2026.
What is Oppenheimer's rating on INSP?
Oppenheimer rates INSP Outperform, a bullish rating, as of Aug 4, 2026.
When did Oppenheimer last change its view on INSP?
On Aug 4, 2026, Oppenheimer upgrades to Outperform from Perform, price target $85.
How does Oppenheimer's INSP target compare with other analysts?
Across 12 firms with a INSP price target in the last 12 months, the median target is $72. Oppenheimer's $85 is 18% above that.

More INSP rating histories

All Oppenheimer ratingsINSP news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.